REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
18 April 2022 - 10:00PM
Heat Biologics, Inc. (“Heat”)
(NYSE American: HTBX), a
clinical-stage biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system and novel
biodefense assets, reminds investors that it will host an investor
and media livestream event on Tuesday, April 19, 2022 at 10:30 AM
Eastern Time to discuss the latest developments. The event will be
broadcast at: https://vimeo.com/event/2027558/fc6de52c31
About Heat Biologics, Inc.Heat
Biologics is a biopharmaceutical company focused on developing
first-in-class therapies and vaccines to modulate the immune
system. Heat’s gp96 platform is designed to activate immune
responses against cancer or infectious diseases. The Company has
multiple product candidates in development leveraging the gp96
platform, including HS-110, which has completed enrollment in a
Phase 2 trial, various infectious disease/biological threat
programs in preclinical development and a pipeline of proprietary
immunomodulatory antibodies and cell-based therapies, including
PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please
visit: www.heatbio.com, and also follow us
on Twitter.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@heatbio.com
Heat Biologics (AMEX:HTBX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Heat Biologics (AMEX:HTBX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
Echtzeit-Nachrichten über Heat Biologics Inc (Amerikanische Börse): 0 Nachrichtenartikel
Weitere News-Artikel